Viewing Study NCT00658632


Ignite Creation Date: 2025-12-24 @ 9:31 PM
Ignite Modification Date: 2026-02-19 @ 11:43 AM
Study NCT ID: NCT00658632
Status: COMPLETED
Last Update Posted: 2016-05-04
First Post: 2008-04-09
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Sponsor: Eisai Inc.
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Gastroesophageal Reflux Disease (GERD) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None GERD View
None erosive GERD View
None erosive esophagitis View